A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)

Table 1 Laboratory and clinical data at baseline and six months (mean ± standard deviation) and statistical significance results

	Baseline	Month 6	*Wilcoxon p-value*
6MWT (meters)	316.88 ± 123.26	345.50 ± 117.68	0.11
BARS score	9.75 ± 6.09	10.06 ± 6.96	0.59
Neuroglyphics Off Target-dominant (%)	19.00 ± 14.11	16.62 ± 10.91	0.69
Neuroglyphics Off Target- Nd (%)	21.19 ± 13.99	17.77 ± 11.65	0.47
BARS Upper score	2.63 ± 2.22	2.75 ± 2.84	0.79
9HP Dom Avg (sec)	28.83 ± 8.23	27.22 ± 7.84	0.38
9HP Dom z-score (sec)	4.35 ± 2.77	4.04 ± 2.77	0.38
9HP Nd Avg (sec)	30.89 ± 15.88	29.84 ± 11.41	0.78
9HP Nd z-score (sec)	4.71 ± 5.39	5.05 ± 4.96	1
GAITRite data:
Cadence (steps/min)	94.33 ± 18.86	99.95 ± 13.88	0.15
Velocity (cm/sec)	97.86 ± 34.08	108.59 ± 33.61	0.15
Step Length (cm)	60.10 ± 12.74	63.68 ± 14.62	0.38
Step Width (cm)	11.72 ± 3.77	11.53 ± 3.46	0.55
Step Time (sec)	0.67 ± 0.15	0.61 ± 0.09	0.11

Avg Average, BARS Brief Ataxia Rating Scale, cm Centimetres, DOM Dominate min Minute, 6MWT 6-min walk test, Nd Non-dominant, sec Seconds, 9HP 9-hole peg test – a brief, standardized and quantitative test of upper extremity (hand and arm) function z-score: calculated by converting raw into a common metric

ISSN: 1750-1172